{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T23:53:55Z","timestamp":1787961235483,"version":"build-2784847793"},"reference-count":54,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2018,1,12]],"date-time":"2018-01-12T00:00:00Z","timestamp":1515715200000},"content-version":"vor","delay-in-days":11,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Human Psychopharmacology"],"published-print":{"date-parts":[[2018,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Agomelatine and vortioxetine are antidepressants with different mechanisms of action compared to other pharmaceutical treatment options. The objective of this present analysis is to determine the relative efficacy and acceptability of agomelatine (25\u201350\u00a0mg) compared to vortioxetine (10\u201315\u201320\u00a0mg) in adult patients with major depressive disorder. We performed an adjusted indirect comparison using placebo as a common control. The main outcomes were efficacy (response to treatment by Montgomery\u2010\u00c5sberg depression rating scale\/Hamilton Rating Scale for Depression) and acceptability (withdrawal rate for any reason or due to adverse events). 10 agomelatine and 11 vortioxetine studies were included in the analysis. For efficacy, no difference was shown between agomelatine and vortioxetine (E[95% CI]\u00a0=\u00a0\u22120.03 [\u22120.12;0.05]). For acceptability, no significant difference was found between both antidepressants.<\/jats:p><jats:p>These findings substantiate current understanding that most antidepressants are of similar average efficacy and tolerability. Such equivalent therapeutic benefit of both compounds, measured by a quantitative clinical research approach, has to be discussed with the knowledge of a qualitative estimation in routine practice.<\/jats:p>","DOI":"10.1002\/hup.2646","type":"journal-article","created":{"date-parts":[[2018,1,12]],"date-time":"2018-01-12T07:52:38Z","timestamp":1515743558000},"source":"Crossref","is-referenced-by-count":1,"title":["Relative short\u2010term efficacy and acceptability of agomelatine versus vortioxetine in adult patients suffering from major depressive disorder"],"prefix":"10.1002","volume":"33","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5339-7185","authenticated-orcid":false,"given":"Sidney H.","family":"Kennedy","sequence":"first","affiliation":[{"name":"University of Toronto, St. Michael's Hospital, Li Ka Shing Knowledge Institute  Toronto Ontario Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean\u2010Marie","family":"Grouin","sequence":"additional","affiliation":[{"name":"INSERM1219 Population Health University of Rouen  Rouen France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"St\u00e9phanie","family":"Cadour","sequence":"additional","affiliation":[{"name":"Biostatistics Department and Neuropsychiatry Center for Therapeutic Innovation Institut de Recherches Internationales Servier (IRIS)  Suresnes France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V\u00e9ronique","family":"Robert","sequence":"additional","affiliation":[{"name":"Biostatistics Department and Neuropsychiatry Center for Therapeutic Innovation Institut de Recherches Internationales Servier (IRIS)  Suresnes France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8232-0793","authenticated-orcid":false,"given":"Fran\u00e7oise","family":"Picarel\u2010Blanchot","sequence":"additional","affiliation":[{"name":"Biostatistics Department and Neuropsychiatry Center for Therapeutic Innovation Institut de Recherches Internationales Servier (IRIS)  Suresnes France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2018,1,12]]},"reference":[{"key":"e_1_2_10_2_1","doi-asserted-by":"publisher","DOI":"10.1017\/S1461145711001027"},{"key":"e_1_2_10_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.euroneuro.2011.11.008"},{"key":"e_1_2_10_4_1","doi-asserted-by":"crossref","DOI":"10.1002\/9780470743386","volume-title":"Multiple Comparisons within a Study, in Introduction to Meta\u2010Analysis","author":"Borenstein M.","year":"2009"},{"key":"e_1_2_10_5_1","doi-asserted-by":"publisher","DOI":"10.1097\/YIC.0000000000000018"},{"key":"e_1_2_10_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0895-4356(97)00049-8"},{"key":"e_1_2_10_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(09)60046-5"},{"key":"e_1_2_10_8_1","volume-title":"Statistical power analysis for the behavioral sciences","author":"Cohen J.","year":"1988"},{"key":"e_1_2_10_9_1","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1038\/nrd3140","article-title":"Agomelatine, the first melatonergic antidepressant: Discovery, characterization and development","volume":"9","author":"Bodinat C.","year":"2010","journal-title":"Nature Reviews. Drug Discovery"},{"key":"e_1_2_10_10_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40263-014-0195-x"},{"key":"e_1_2_10_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(09)60978-8"},{"key":"e_1_2_10_12_1","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-155-11-201112060-00009"},{"key":"e_1_2_10_13_1","first-page":"CD008851","article-title":"Agomelatine versus other antidepressive agents for major depression","volume":"12","author":"Guaiana G.","year":"2013","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"e_1_2_10_14_1","doi-asserted-by":"publisher","DOI":"10.1111\/bph.12720"},{"key":"e_1_2_10_15_1","doi-asserted-by":"publisher","DOI":"10.1097\/YIC.0b013e32833a86aa"},{"key":"e_1_2_10_16_1","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.11m07470"},{"key":"e_1_2_10_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(11)60095-0"},{"key":"e_1_2_10_18_1","doi-asserted-by":"publisher","DOI":"10.1002\/sim.1186"},{"issue":"1","key":"e_1_2_10_19_1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1037\/a0038550","article-title":"A brief history of the development of antidepressant drugs: From monoamines to glutamate","volume":"13","author":"Hillhouse T. M.","year":"2015","journal-title":"Experimental and Clinical Psychopharmacology"},{"key":"e_1_2_10_20_1","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.11r07485"},{"key":"e_1_2_10_21_1","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.14m09335"},{"key":"e_1_2_10_22_1","doi-asserted-by":"publisher","DOI":"10.1097\/YIC.0b013e328359768e"},{"key":"e_1_2_10_23_1","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.09m05347blu"},{"key":"e_1_2_10_24_1","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1016\/j.euroneuro.2015.09.006","article-title":"Sustained efficacy of agomelatine 10mg, 25mg, and 25\u201050mg on depressive symptoms and functional outcomes in patients with major depressive disorder. A placebo\u2010controlled study over 6 months","volume":"26","author":"Kennedy S. H.","year":"2015","journal-title":"European Neuropsychopharmacology"},{"key":"e_1_2_10_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.euroneuro.2014.01.006"},{"key":"e_1_2_10_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.euroneuro.2005.09.002"},{"key":"e_1_2_10_27_1","doi-asserted-by":"publisher","DOI":"10.1097\/JCP.0b013e318172b48c"},{"key":"e_1_2_10_28_1","doi-asserted-by":"publisher","DOI":"10.2165\/11534420-000000000-00000"},{"key":"e_1_2_10_29_1","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v68n1112"},{"key":"e_1_2_10_30_1","doi-asserted-by":"publisher","DOI":"10.1185\/03007995.2014.969566"},{"key":"e_1_2_10_31_1","doi-asserted-by":"publisher","DOI":"10.1097\/00004850-200209000-00004"},{"key":"e_1_2_10_32_1","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.14m09337"},{"key":"e_1_2_10_33_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00213-014-3839-0"},{"key":"e_1_2_10_34_1","doi-asserted-by":"publisher","DOI":"10.1038\/npp.2015.52"},{"key":"e_1_2_10_35_1","doi-asserted-by":"publisher","DOI":"10.1093\/ijnp\/pyw003"},{"key":"e_1_2_10_36_1","doi-asserted-by":"publisher","DOI":"10.1097\/JCP.0b013e31825d6c25"},{"key":"e_1_2_10_37_1","doi-asserted-by":"publisher","DOI":"10.1017\/S1461145714000546"},{"key":"e_1_2_10_38_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13643-015-0001-y"},{"key":"e_1_2_10_39_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.euroneuro.2008.06.003"},{"key":"e_1_2_10_40_1","doi-asserted-by":"publisher","DOI":"10.1002\/hup.2424"},{"issue":"5","key":"e_1_2_10_41_1","first-page":"661","article-title":"Efficacy of agomelatine, a MT1\/MT2 receptor agonist with 5\u2010HT2C antagonistic properties, in major depressive disorder","volume":"10","author":"Oli\u00e9 J. P.","year":"2007","journal-title":"International Journal of Neuropsychopharmacology"},{"key":"e_1_2_10_42_1","doi-asserted-by":"publisher","DOI":"10.1586\/14737175.2016.1173545"},{"key":"e_1_2_10_43_1","doi-asserted-by":"publisher","DOI":"10.1503\/jpn.140120"},{"key":"e_1_2_10_44_1","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.14r09297"},{"key":"e_1_2_10_45_1","doi-asserted-by":"publisher","DOI":"10.1177\/1060028014528305"},{"key":"e_1_2_10_46_1","doi-asserted-by":"publisher","DOI":"10.1097\/YIC.0b013e328349b117"},{"key":"e_1_2_10_47_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jad.2009.01.029"},{"issue":"5","key":"e_1_2_10_48_1","doi-asserted-by":"crossref","first-page":"616","DOI":"10.4088\/JCP.09m05471blu","article-title":"Agomelatine in the treatment of major depressive disorder: An 8\u2010week, multicenter, randomized, placebo\u2010controlled trial","volume":"71","author":"Stahl S. M.","year":"2010","journal-title":"Journal of Clinical Psychiatry"},{"key":"e_1_2_10_49_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.g1888"},{"key":"e_1_2_10_50_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.euroneuro.2016.03.007"},{"key":"e_1_2_10_51_1","doi-asserted-by":"publisher","DOI":"10.1002\/sim.1187"},{"key":"e_1_2_10_52_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.287.14.1840"},{"key":"e_1_2_10_53_1","volume-title":"Meta\u2010analysis of controlled clinical trials","author":"Whitehead A.","year":"2003"},{"key":"e_1_2_10_54_1","doi-asserted-by":"publisher","DOI":"10.1097\/JCP.0b013e3181d420a7"},{"key":"e_1_2_10_55_1","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.14r09164"}],"container-title":["Human Psychopharmacology: Clinical and Experimental"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fhup.2646","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/hup.2646","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,28]],"date-time":"2023-09-28T01:45:17Z","timestamp":1695865517000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/hup.2646"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,1]]},"references-count":54,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,1]]}},"alternative-id":["10.1002\/hup.2646"],"URL":"https:\/\/doi.org\/10.1002\/hup.2646","archive":["Portico"],"relation":{},"ISSN":["0885-6222","1099-1077"],"issn-type":[{"value":"0885-6222","type":"print"},{"value":"1099-1077","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,1]]},"article-number":"e2646"}}